Luye Pharma Group ( (HK:2186) ) has provided an announcement.
Luye Pharma Group Ltd. has announced a board meeting scheduled for March 28, 2025, to approve the company’s annual results for the year ending December 31, 2024, and to consider the payment of a final dividend. This meeting is significant as it will determine the company’s financial performance and potential shareholder returns, impacting its market position and stakeholder interests.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company engaged in the development, production, and sale of innovative medications. The company operates in the healthcare industry, focusing on providing advanced therapeutic solutions to meet diverse medical needs.
YTD Price Performance: 10.0%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.1B
For a thorough assessment of 2186 stock, go to TipRanks’ Stock Analysis page.